What question did this study set out to answer?

The study aimed to assess the safety and efficacy of CTX110 in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

May 7, 2026Blood AdvancesOpen Access

Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma

View Full Paper

Ask AI

Bookmark

The study aimed to assess the safety and efficacy of CTX110 in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Single-arm phase 1/2 trial involving two treatment courses with CD19-directed CAR-T therapy.
Evaluated dose levels 1-4 with 1 or 2 infusions among 63 heavily pretreated patients.
Primary endpoints were incidence of dose-limiting toxicities and objective response rate.
Among patients who received DL≥3, the objective response rate was 65% and complete response rate was 39%.
The two-infusion regimen showed improved response duration (HR 0.65).
54% experienced cytokine release syndrome and 32% had serious adverse events.

No takes yet. Share an insight, caveat, or question.

Randomized trial evaluates safety and efficacy in relapsed/refractory B-cell non-Hodgkin lymphoma, indicating potential benefits of treatment.

McGuirk et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial evaluates safety and efficacy in relapsed/refractory B-cell non-Hodgkin lymphoma, indicating potential benefits of treatment.